Safety Study of BMS-986016 With or Without Nivolumab in Patients With Advanced Solid Tumors

NCT02966548 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

35

Enrollment

INDUSTRY

Sponsor class

Conditions

Cancer

Interventions

DRUG: Relatlimab
DRUG: Nivolumab

Sponsor

Bristol-Myers Squibb

Collaborators

[object Object]